...
首页> 外文期刊>Chemical research in toxicology >Probe Molecule (PrM) Approach in Adverse Outcome Pathway (AOP) Based High-Throughput Screening (HTS): In Vivo Discovery for Developing in Vitro Target Methods
【24h】

Probe Molecule (PrM) Approach in Adverse Outcome Pathway (AOP) Based High-Throughput Screening (HTS): In Vivo Discovery for Developing in Vitro Target Methods

机译:基于不良结果途径(AOP)的探针分子(PrM)方法高通量筛选(HTS):体内发现以开发体外靶标方法

获取原文
获取原文并翻译 | 示例
           

摘要

Efficient and accurate adverse outcome pathway (AOP) based high-throughput screening (HTS) methods use a systems biology based approach to computationally model in vitro cellular and molecular data for rapid chemical prioritization; however, not all HTS assays are grounded by relevant in vivo exposure data. The challenge is to develop HTS assays with unambiguous quantitative links between in vitro responses and corresponding in vivo effects, which is complicated by metabolically insufficient systems, in vitro to in vivo extrapolation (IVIVE), cross-species comparisons, and other inherent issues correlating IVIVE findings. This article introduces the concept of ultrasensitive gas phase probe molecules (PrMs) to help bridge the current HTS assay IVIVE gap. The PrM concept assesses metabolic pathways that have already been well-defined from intact human or mammalian models. Specifically, the idea is to introduce a gas phase probe molecule into a system, observe normal steady state, add chemicals of interest, and quantitatively measure (from headspace gas) effects on PrM metabolism that can be directly linked back to a well-defined and corresponding in vivo effect. As an example, we developed the pharmacokinetic (PK) parameters and differential equations to estimate methyl tertiary butyl ether (MTBE) metabolism to tertiary butyl alcohol (TBA) via cytochrome (CYP) 2A6 in the liver from human empirical data. Because MTBE metabolic pathways are well characterized from in vivo data, we can use it as a PrM to explore direct and indirect chemical effects on CYP pathways. The PrM concept could be easily applied to in vitro and alternative models of disease and phenotype, and even test for volatile chemicals while avoiding liquid handling robotics. Furthermore, a PrM can be designed for any chemical with known empirical human exposure data and used to assess chemicals for which no information exists. Herein, we propose an elegant gas phase probe molecule-based approach to in vitro toxicity testing.
机译:基于高效和准确的不良结果途径(AOP)的高通量筛选(HTS)方法使用基于系统生物学的方法对体外细胞和分子数据进行计算机建模,以快速确定化学物质的优先级。但是,并非所有的HTS分析都以相关的体内暴露数据为基础。面临的挑战是要开发出在体外反应与相应的体内效应之间具有明确定量联系的HTS分析,而代谢方面的系统不足,体外-体内外推(IVIVE),种间比较以及与IVIVE相关的其他内在问题将使这种复杂化变得复杂发现。本文介绍了超灵敏气相探针分子(PrMs)的概念,以帮助弥合当前的HTS分析IVIVE差距。 PrM概念评估了完整人类模型或哺乳动物模型中已经明确定义的代谢途径。具体而言,该想法是将气相探针分子引入系统,观察正常的稳态,添加目标化学物质,并定量测量(来自顶空气体)对PrM代谢的影响,这些作用可直接链接到定义明确且相应的体内作用。例如,我们开发了药代动力学(PK)参数和微分方程,以根据人类经验数据,通过肝脏中的细胞色素(CYP)2A6估算甲基叔丁基醚(MTBE)代谢为叔丁醇(TBA)。由于从体内数据可以很好地表征MTBE代谢途径,因此我们可以将其用作PrM来探索对CYP途径的直接和间接化学作用。 PrM概念可以轻松应用于疾病和表型的体外模型和替代模型,甚至可以测试挥发性化学物质,同时避免使用液体处理机器人。此外,PrM可以针对具有已知人体经验数据的任何化学品进行设计,并用于评估不存在任何信息的化学品。在此,我们提出了一种基于气相探针分子的优雅方法进行体外毒性测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号